Vectura Receives Bulgarian Marketing Authorisation For Inhaler
LONDON (Alliance News) – Vectura Group PLC Tuesday said partner Sandoz has received marketing authorisation from Bulgarian authorities for its new inhaler for patients with respiratory problems.
It has previously been launched in Denmark, and authorised in Germany, Sweden, Hungary and Romania.
“Bulgaria has approved the 50µg-500µg dosage form for the continuous treatment of patients above 12 years of age with persistent asthma or for symptomatic treatment of [chronic obstructive pulmonary disease]. The product’s safety, efficacy and equivalence have been proven in multiple clinical trials,” the company said in a statement.
Vectura initially developed the product and created the design of the inhaler, before licensing the asset to Sandoz in 2006. It was subsequently developed in collaboration with Vectura.